Insider Transactions in Q3 2024 at Igm Biosciences, Inc. (IGMS)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,734
+15.68%
|
-
|
|
Sep 30
2024
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,734
+0.06%
|
-
|
|
Sep 30
2024
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
2,687
+5.2%
|
-
|
|
Sep 30
2024
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
1,734
+1.93%
|
-
|
|
Sep 30
2024
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
3,078
+15.96%
|
-
|
|
Sep 30
2024
|
Elizabeth H.Z. Thompson |
BUY
Grant, award, or other acquisition
|
Direct |
1,452
+25.0%
|
-
|
|
Sep 30
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
3,988
+0.31%
|
-
|
|
Sep 13
2024
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,487
-1.2%
|
$16,357
$11.54 P/Share
|
|
Sep 13
2024
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,487
-0.95%
|
$16,357
$11.54 P/Share
|
|
Sep 13
2024
|
Steven Weber PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
469
-1.8%
|
$5,159
$11.54 P/Share
|
|
Sep 13
2024
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,487
-0.61%
|
$16,357
$11.54 P/Share
|
|
Sep 13
2024
|
Fred Schwarzer CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
3,946
-1.55%
|
$43,406
$11.54 P/Share
|
|
Sep 13
2024
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
925
-1.16%
|
$10,175
$11.54 P/Share
|
|
Sep 13
2024
|
Mary Beth Harler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,487
-0.9%
|
$16,357
$11.54 P/Share
|
|
Aug 08
2024
|
William Strohl |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+50.0%
|
-
|
|
Jul 25
2024
|
Julie Hambleton |
SELL
Open market or private sale
|
Direct |
15,132
-88.33%
|
$211,848
$14.0 P/Share
|
|
Jul 25
2024
|
Julie Hambleton |
BUY
Exercise of conversion of derivative security
|
Direct |
15,132
+46.9%
|
$15,132
$1.39 P/Share
|
|
Jul 19
2024
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
46,666
+8.25%
|
-
|
|
Jul 19
2024
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
35,333
+11.56%
|
-
|
|
Jul 19
2024
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+16.65%
|
-
|
|
Jul 19
2024
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+10.93%
|
-
|
|
Jul 19
2024
|
Mary Beth Harler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+20.66%
|
-
|